Back to All

Diaceutics to present Workshop at EORTC

10 October, 2019

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will attend the EORTC (European Organisation for Research and Treatment of Cancer) Melanoma meeting in Florence on 10 October 2019. Dr. Marianna Sciortino, Director of the Global Laboratory Team at Diaceutics will participate in a workshop entitled “Emerging biomarkers in melanoma treatment: are we ready for the challenge?” Diaceutics have been invited to present by one of the top EU melanoma experts, Professor Daniela Massi.

Dr. Sciortino will discuss the current biomarkers necessary for identifying patients for treatment with currently available targeted therapies and new emerging biomarkers that could be important for future treatments. The Company will highlight the evidence surrounding the predictive role of PD-L1, TMB and NTRK biomarkers, discussing the challenges of how these markers are used in clinical practice.

The EORTC Melanoma group is one of the largest melanoma networks in the world, and conducts clinical trials and translational research in the melanoma field. Its objectives are to improve clinical care of patients suffering with cutaneous or ocular melanoma, and to increase knowledge about melanoma acquisition and progression.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.